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Abstract
Background: Nicotine replacement therapy (NRT) is used by smokers wanting to reduce their smoking and to quit.
However, there are very little data on nicotine intake associated with NRT use in representative population samples. This
study aimed to provide estimates for NRT use and associated nicotine exposure among smokers, recent and longer-term ex-
smokers in England, a country with a permissive regulatory regime for nicotine substitution.
Methods: In the Smoking Toolkit Study, a monthly series of representative household surveys of adults aged 16+ in
England, current and recent ex-smokers who agreed to be re-contacted were followed up 6 months later and standard
socio-demographic and smoking characteristics assessed (N = 5,467, response rate 25.1%). A random sub-sample (N = 1,614;
29.5%) also provided saliva, analysed for cotinine.
Results: The sample followed up was broadly representative of the original sample. At follow-up, 11.8% (95%CI 10.9–12.8,
N = 565) of current smokers, 34.8% (95%CI 28.9–41.3, N = 77) of recent (#3 months) ex-smokers, and 7.8% (95%CI 5.6–10.6,
N = 36) of longer-term (.3 months) ex-smokers reported using NRT. Smokers who used NRT had similar saliva cotinine
concentrations to smokers who did not use NRT (mean 6 sd = 356.06198.6 ng/ml vs. 313.16178.4 ng/ml). Recent ex-
smokers who used NRT had levels that were somewhat lower, but not significantly so, than current smokers
(216.76179.3 ng/ml). Longer-term ex-smokers using NRT had still lower levels (157.36227.1 ng/ml), which differed
significantly from smokers using NRT (p = 0.024).
Conclusions: Concurrent use of nicotine replacement therapy while smoking is relatively uncommon and is not associated
with higher levels of nicotine intake. Among ex-smokers, NRT use is common in the short but not longer-term and among
longer-term users is associated with lower nicotine intake than in smokers.
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Introduction
Harm reduction may be defined as reducing psychological or
physiological harm from substance use without complete cessation
[1]. In the case of tobacco use, harm reduction can involve the
partial substitution of cigarettes with non-combustible forms such
as nicotine replacement therapy (NRT) to reduce cigarette
consumption or for temporary abstinence. Harm reduction may
also constitute the complete and permanent substitution of
cigarettes with less harmful products, switching smokers from
combustible to non-combustible nicotine delivery devices, includ-
ing NRT [2].
The rationale for harm reduction with NRT is based on the
knowledge that most harm is caused by the burning of tobacco and
not nicotine per se [3]. There is evidence from both population
studies and clinical trials that the use of NRT among current
smokers can result in reduced cigarette consumption [4].
Moreover, it is associated with both increased motivation to stop
and improved quit rates [1,5] and does not increase overall
nicotine intake [6]. Permanent replacement of cigarettes with
NRT among ex-smokers has been shown to result in 40% of
baseline levels of nicotine being substituted by nicotine replace-
ment products in clinical trials [7,8]. Trials have also shown that
extended use of NRT by ex-smokers may result in better long-term
abstinence rates [9,10].
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For this reason, NRT licensing is being changed to allow its use
for harm reduction purposes among current and ex-smokers
[11,12]. Yet, little real world data exist on the impact of NRT use
for harm reduction. Most data come from clinical trials which are
limited by the fact that trial samples tend to differ from general
population samples [13] and that NRT is provided free together
with behavioural support which may influence usage patterns. By
contrast, most NRT is used without advice and bought over the
counter [14] and given the recent proliferation of available
products [15], up-to-date information is needed. In the UK, NICE
therefore has called for further research in the area of harm
reduction [16] as investigating this issue will allow more precise
quantification of the likely benefits or harms of substituting
cigarettes with NRT among current and ex-smokers.
As a first step in this direction, this report describes the
prevalence of NRT use and associated exposure to nicotine in
three conditions that it might be used in a general population
sample: among current smokers for temporary abstinence or
smoking reduction, during a quit attempt by recent ex-smokers or
for subsequent maintenance of quitting by longer-term ex-
smokers. Although it is unlikely that a substantially increased
nicotine intake from NRT would be harmful [17,18], it clearly is a
concern for some people and a potential barrier to effective use of
nicotine products [19]. Moreover, the question has been raised
whether NRT use perpetuates nicotine dependence [20] and this
issue can be addressed by looking at relative exposure to nicotine
among ex-smokers using and not using NRT as compared with
current smokers. Lastly, given that NRT is mainly used over the
counter, focusing on real-life general population data provides the
best insight into this topic from a public health perspective.
Specifically, this study aimed to answer the following research
questions:
1) What is the prevalence of NRT use among current smokers,
recent (#3 months) and longer-term (.3 months) ex-smokers?
2) What is the nicotine intake associated with NRT use among
current smokers, recent (#3 months) and longer-term (.3
months) ex-smokers?
Methods
Study design and sampling
The data come from follow-up waves of the Smoking Toolkit
Study (www.smokinginengland.info), which is an ongoing series of
cross-sectional household surveys in England designed to provide
information about smoking prevalence and behaviour. Each
month a new sample of approximately 1,800 adults aged 16 and
over completes a face to face computer-assisted survey with a
trained interviewer. Current smokers and ex-smokers who have
quit within the last year are asked at baseline whether they agree to
be followed up and those consenting are re-contacted via a postal
questionnaire at 6 months. Half of those who are followed up are
randomised to receive also a saliva kit and asked to provide a
sample. The survey methodology has been described in detail
elsewhere and has been shown to result in a baseline sample that is
nationally representative in its socio-demographic composition
and proportion of smokers [21]. Participants provided verbal
consent. As this was an omnibus household survey conducted
every week by the survey company and data were anonymised,
written consent was not required. Verbal consent was noted by the
interviewer and ethics approval for this study and the consent
procedure was granted by the University College London ethics
committee.
Participants
Between November 2006 (the survey start) and July 2011 (when
follow-up saliva collection was paused), 21,821 current smokers and
recent ex-smokers at baseline agreed to be followed up. Of these,
5,539 responded at 6 months follow-up. Seventy-two participants
(1.3%) were excluded due to missing information on NRT use or
smoking status which resulted in a response rate of 25.1% and a
total analytic sample of N=5,467, of whom 29.5% (N=1,614) also
provided saliva.
Measures
At baseline, standard socio-demographic characteristics includ-
ing age, gender and social-grade (AB = higher and intermediate
professional/managerial, C1 = supervisory, clerical, junior
managerial/administrative/professional, C2 = skilled manual
workers, D= semi-skilled and unskilled manual workers, E= on
state benefit, unemployed, lowest grade workers) were assessed.
Participants were asked if they (a) smoked cigarettes (including
hand-rolled) every day; (b) smoked cigarettes (including hand-
rolled) but not every day; (c) did not smoke cigarettes at all but did
smoke tobacco of some kind (e.g. pipe or cigar); (d) had stopped
smoking completely in the last year; (e) had stopped smoking
completely more than a year ago; or (f) had never been a smoker
(i.e. smoked for a year or more). Current smokers, classified as
answering ‘yes’ to (a) or (b), and recent ex-smokers, classified as
answering ‘yes’ to (d), were eligible for follow-up. Those answering
‘yes’ to (c), (e) or (f) were excluded from analysis. Additionally,
current smokers were asked questions to determine nicotine
dependence (measured by heaviness of smoking index, HSI [22],
and strength of urges to smoke, SUTS [23]) as well as motivation
to quit (measured by the motivation to stop scale, MTSS [24]).
At 6-months follow-up, all participants were asked whether they
smoked cigarettes at all nowadays, including hand-rolled cigarettes
(Yes/No). Those who self-classified as smokers were asked whether
they were trying to reduce how much they smoked and, if so,
whether they used NRT for cutting down and/or temporary
abstinence (Yes/No). Those who had stopped smoking were asked
how long ago they had stopped smoking, categorised into ex-
smokers who had stopped up to three months ago or more than
three months ago, whether they had used NRT to help them stop,
and if so, whether they still used NRT (Yes/No). We chose this
cut-off to distinguish standard from longer-term NRT use because
three months is the standard recommendation for treatment
length. As postal collection of saliva for cotinine analysis, a reliable
marker of nicotine intake, has been shown to be practical and
reliable [25], saliva was collected with a postal saliva sample kit at
follow-up. The kit contained a salivette cotton roll and instructions
on how to collect the sample. Participants then returned the kit by
post directly to the laboratory where it was assayed for cotinine
using rapid liquid-gas chromatograpy [26].
Analysis
Data were analysed with IBM SPSS Statistics 20.0.0. Compar-
isons were made between those who were and were not followed
up and among those who were followed-up, between those who
did and did not provide a saliva sample. Differences were assessed
with x2-tests and independent t-tests for categorical and contin-
uous variables, respectively. Due to the positively skewed
distribution of cotinine values, generalised linear models with a
gamma distribution and log link were used to determine the
impact of NRT use and smoking status on cotinine values. In
sensitivity analysis, findings were re-examined with a general linear
model using log-transformed cotinine values (all zero values being
replaced with 0.001). Given unequal group sizes and non-
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normality of cotinine values, post-hoc analyses of group differences
were assessed with Kruskal-Wallis pairwise comparison. All
analyses were unweighted, statistical significance was set at the
standard level (p,0.05), and the Bonferroni correction was
applied in post-hoc analyses.
Results
1. Prevalence of NRT use among current smokers, recent
and longer-term ex-smokers
Participants followed-up at 6 months who constituted the
analytic sample were somewhat older and more likely to be female
than those lost to follow-up (Table 1). The majority of the analytic
sample, 87.5% (95%CI 86.6–88.3, N= 4,783/5,467), were smok-
ing, 4.0% (95%CI 3.6–4.6, N=221/5,467) had stopped smoking
up to three months ago and 8.5% (95%CI 7.8–9.2, N=463/
5,467) more than three months ago. NRT use was most common
among recent (#3 months) ex-smokers, a third of whom (34.8%,
95%CI 28.9–41.3, N=77/221) were still using NRT. A signifi-
cantly smaller proportion of current smokers (11.8%; 95%CI
10.9–12.8, N= 565/4,783; x2(1) = 100.2, p,0.001) or longer-term
(.3 months) ex-smokers (7.8%; 95%CI 5.6–10.6, N= 36/463;
x2(1) = 79.5, p,0.001), were currently using NRT.
2. Nicotine intake associated with NRT use among
current smokers, recent and longer-term ex-smokers
A subsample of the analytic sample provided a saliva sample,
analysed for cotinine to estimate exposure to nicotine. Socio-
demographic and smoking characteristics did not differ as a
function of whether participants did or did not have cotinine
results (all p.0.05, Table 1). In addition, the prevalence of NRT
use among either current or ex-smokers did not differ as a function
of cotinine availability (all p.0.05). In the presence of a significant
interaction between NRT use and smoking status (Wald
x2(2) = 55.7, p,0.001), main effects were not considered. As
Figure 1 shows, cotinine levels were greatest among current
smokers and lowest among longer-term ex-smokers but also
differed as a function of NRT use.
Among participants not using NRT, cotinine levels were signifi-
cantly higher in smokers (arithmetic mean (~xa) 6 sd =313.16
178.4 ng/ml, geometric mean (~xg) = 226.0 ng/ml, N=1,263) than ex-
smokers. This was the case for both recent ex-smokers
(~xa =16.1651.1 ng/ml, ~xg =1.8 ng/nl, N=47; Kruskal-Wallis pair-
wise comparison =729.7, p,0.001) and longer-term ex-smokers
(~xa =3.8618.8 ng/ml, ~xg =0.6 ng/ml, N=120; Kruskal-Wallis pair-
wise comparison =789.6, p,0.001). Yet, even among ex-smokers
there was some variation and some 7.2% (N=12) had cotinine values
above standard cut-off levels for smoking abstinence ($15 ng/ml),
most likely due to misreporting.
Among participants using NRT, cotinine levels of current
smokers (~xa =356.06198.6 ng/ml, ~xg =283.6 ng/ml; N=155)
were significantly higher only compared with longer-term ex-
smokers (~xa =157.36227.1 ng/ml, ~xg =34.2 ng/ml, N= 9; Krus-
kal-Wallis pairwise comparison = 504.5; p = 0.024). Cotinine
levels of recent ex-smokers using NRT (~xa =216.76179.3 ng/
ml, ~xg =113.3 ng/nl, N= 20) did not differ from current smokers
using NRT (Kruskal-Wallis pairwise comparison = 317.0;
p = 0.063). Excluding recent ex-smokers who had stopped within
the last week (N= 32) did not change results.
Further pairwise comparisons revealed that recent ex-smokers
using NRT had significantly higher cotinine levels than recent ex-
smokers not using NRT (Kruskal-Wallis pairwise comparison
= 503.0, p,0.001). Longer-term ex-smokers using NRT also
appeared to have higher cotinine levels than long-term ex-smokers
not using NRT but this difference did not reach significance
(Kruskal-Wallis pairwise comparison = 375.4; p = 0.297). Lastly,
smokers with concurrent NRT use had similar cotinine values to
those not using NRT (Kruskal-Wallis pairwise comparison = 90.2;
p = 0.344) and this remained the case when controlling for
cigarette consumption in sensitivity analysis. Excluding partici-
pants who had indicated ever using electronic cigarettes at baseline
(N= 9) did not alter results.
Table 1. Baseline characteristics by follow-up status and cotinine availability.
Total sample
(N=21821)
Not followed-up
(N=16354)
Followed-up
(N=5467) Cotinine analysed
Yes (N=1614) No (N=3853)
Socio-demographic characteristics
Mean (SD) Age 41.6 (16.3) 39.8 (16.1) 47.0 (15.6)*** 46.8 (15.8) 47.1 (15.5)
% (N) Women 53.1 (11589) 51.9 (8493) 56.6 (3096)*** 55.5 (895) 57.1 (2201)
% (N) C2DE1 67.8 (14788) 68.1 (11132) 66.9 (3656) 66.7 (1076) 67.0 (2580)
Smoking characteristics
% (N) Current Smokers 93.7 (20445) 94.3 (15426) 91.8 (5019)*** 91.5 (1477) 91.9 (3542)
Mean (SD) Heaviness of smoking index‘ 2.25 (1.5) 2.22 (1.5) 2.35 (1.5)*** 2.41 (1.5) 2.33 (1.5)
Mean (SD) Strength of urges‘2 2.29 (0.9) 2.28 (0.9) 2.32 (0.9)** 2.32 (0.9) 2.30 (0.9)
Mean (SD) Motivation to stop‘3 3.85 (2.0) 3.92 (2.0) 3.64 (2.0)*** 3.67 (2.0) 3.62 (2.0)
1In socio-economic group C2 (Skilled manual worker), D (Semi-skilled and unskilled manual worker), or E (On state benefit, unemployed, lowest grade workers);
2From 1 ‘slight’ to 5 ‘extremely strong’;
3From 1 ‘Don’t want to stop’ to 7 ‘Really want to and intend to stop in next month’,
‘Only current smokers included;
*p,.05;
**p,.01;
***p,.001.
doi:10.1371/journal.pone.0113045.t001
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Discussion
Whilst a third of ex-smokers in England use nicotine replace-
ment therapy for smoking cessation in the short-term, its use for
harm reduction is relatively uncommon. Only around one in ten
smokers uses NRT concurrently and a similar proportion of ex-
smokers uses NRT beyond the standard length of three months.
Despite recent policy and licensing changes, long-term NRT use
does not appear to have increased materially since 2002, when one
year usage rates were estimated at around 5% [27]. Similarly,
concurrent NRT use among smokers, either for temporary
abstinence or cutting down, has remained relatively stable since
2002 [28] and mostly reflects short-term use [29]. These findings
are in agreement with a similar lack of change in general NRT
usage pattern following an earlier relaxation of NRT licensing in
2005 [30].
Notwithstanding concerns among potential users and stop
smoking advisors (e.g. [19]), what little research exists suggests that
long-term NRT use is safe and any associated health risks small
[17,31,32], certainly compared with continued smoking [33]. This
study adds further evidence, suggesting that longer-term NRT use
is associated with significantly lower exposure to nicotine than
among current smokers. By contrast, recent ex-smokers using
NRT had concentrations not greatly dissimilar to those of
smokers. This finding is consistent with previous clinical studies
which show that nicotine substitution from NRT tapers off over
time [7]. In line with other work from the Smoking Toolkit Study,
NRT use among current smokers was not associated with greater
cotinine levels [6,34], suggesting that smokers are relatively adept
at titrating nicotine levels, with some nicotine otherwise obtained
from cigarettes being replaced by nicotine from NRT. While this
study cannot provide exact estimates of substitution rates as no
NRT usage data were available, some substitution is likely given
previous findings of smokers maintaining nicotine levels when
using acute forms of NRT whilst dramatically reducing cigarette
consumption [4]. The fact that longer-term use among ex-smokers
was associated with lower cotinine levels suggests that NRT is
unlikely to maintain nicotine dependence in the long run. These
results should allay the fears of potential NRT users that it will lead
to an increase in nicotine exposure.
This study has a number of limitations. Despite an initial large
sample size, there were few ex-smokers who used NRT which
reduced power to detect differences between groups. In addition,
Figure 1. Box-plot of cotinine levels by NRT use and smoking status. Box provides interquartile range and median value is indicated by black
line; whiskers represent normal range (up to 1.5 times of interquartile range); circle indicates outliers 1.5–3 times of the interquartile range and
asterisks extreme outliers more than 3 times of the interquartile range; ‘Plotted on logarithmic scale.
doi:10.1371/journal.pone.0113045.g001
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the baseline sample differed somewhat from the sample followed
up. However, differences were modest and unlikely to substantially
influence the findings. Lastly, due to the cross-sectional design we
cannot make causal attributions about the direction of the
observed effects. This study’s strengths include the use of a
general population sample enabling us to look at actual use of
NRT and assessment with established, ecologically valid measures.
Further research would benefit from measuring a wider array of
biomarkers of smoking-related harm such as lung function tests or
carcinogen metabolites to complement these results and provide a
more complete assessment of the potential harm of long-term
NRT use.
In conclusion, use of NRT while smoking is not associated with
higher overall nicotine levels; its use for more than 3 months after
stopping is uncommon and is associated with significantly lower
cotinine levels compared with current smokers.
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